Figure 2.

Kaplan–Meier plots of efficacy of NVX-CoV2373 against symptomatic coronavirus disease 2019 (COVID-19) in the per-protocol and intention-to-treat analysis sets. Cumulative incidence of symptomatic COVID-19 in the intent-to-treat population (A) and the per-protocol population (B). The timing of surveillance for symptomatic COVID-19 began after the first dose (intention-to-treat population) and at least 7 days after the administration of the second dose (per-protocol population) of vaccine or placebo (ie, on day 28) through a median of approximately 4.5 months of follow-up.